REM Sleep Deprivation Reverses Neurochemical and Other Depressive-Like Alterations Induced by Olfactory Bulbectomy

Molecular Neurobiology

Volumn 51, Issue 1, 2015, Pages 349-360

  Maturana, Maira J ^a   Pudell, Cláudia ^a   Targa, Adriano D S ^a   Rodrigues, Laís S ^a   Noseda, Ana Carolina D ^a   Fortes, Mariana H ^a   dos Santos, Patrícia ^a   Da Cunha, Cláudio ^a   Zanata, Sílvio M ^a   Ferraz, Anete C ^a   Lima, Marcelo M S ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Bulbectomy; Dopamine; Intranigral; Parkinson s disease; REM sleep deprivation; Substantia nigra pars compacta

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BRAIN DERIVED NEUROTROPHIC FACTOR;

ANIMAL; ANIMAL BEHAVIOR; COMPLICATION; DEPRESSION; DISEASE MODEL; HIPPOCAMPUS; MALE; METABOLISM; METABOLOME; MOTOR ACTIVITY; OLFACTORY BULB; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REM SLEEP; SLEEP DEPRIVATION; SUBSTANTIA NIGRA; SURGERY; SWIMMING; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; METABOLOME; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; OLFACTORY BULB; RATS, WISTAR; SLEEP DEPRIVATION; SLEEP, REM; SUBSTANTIA NIGRA; SWIMMING;

EID: 84939889860     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8721-x     Document Type: Article

References (56)

1. Schulte W (1966) Kombinierte Psycho- und Pharmakotherapie bei Melancholikern. Probleme der pharmakopsychiatrischen Kombinations- und Langzeitbehandlung. Karger
2. Gorgulu Y, Caliyurt O (2009) Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. Brain Res Bull 80(3):158–162
3. Landsness EC, Goldstein MR, Peterson MJ, Tononi G, Benca RM (2011) Antidepressant effects of selective slow wave sleep deprivation in major depression: a high-density EEG investigation. J Psychiatr Res 45(8):1019–1026. doi:10.1016/j.jpsychires.2011.02.003
4. Kreuzer PM, Langguth B, Schecklmann M, Eichhammer P, Hajak G, Landgrebe M (2012) Can repetitive transcranial magnetic stimulation prolong the antidepressant effects of sleep deprivation? Brain Stimul 5(2):141–147. doi:10.1016/j.brs.2011.02.005
5. Giedke H, Schwarzler F (2002) Therapeutic use of sleep deprivation in depression. Sleep Med Rev 6(5):361–377
6. Palagini L, Baglioni C, Ciapparelli A, Gemignani A, Riemann D (2013) REM sleep dysregulation in depression: state of the art. Sleep Med Rev 17(5):377–390. doi:10.1016/j.smrv.2012.11.001
7. Zant JC, Leenaars CH, Kostin A, Van Someren EJ, Porkka-Heiskanen T (2011) Increases in extracellular serotonin and dopamine metabolite levels in the basal forebrain during sleep deprivation. Brain Res 1399:40–48. doi:10.1016/j.brainres.2011.05.008
8. Meyers N, Fromm S, Luckenbaugh DA, Drevets WC, Hasler G (2011) Neural correlates of sleepiness induced by catecholamine depletion. Psychiatry Res 194(1):73–78. doi:10.1016/j.pscychresns.2011.06.015
9. Sei H, Saitoh D, Yamamoto K, Morita K, Morita Y (2000) Differential effect of short-term REM sleep deprivation on NGF and BDNF protein levels in the rat brain. Brain Res 877(2):387–390
10. Wang YQ, Tu ZC, Xu XY, Li R, Qu WM, Urade Y, Huang ZL (2012) Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats. J Neurochem 120(2):314–324. doi:10.1111/j.1471-4159.2011.07558.x
11. Vogel GW (1983) Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry 7(2–3):343–349
12. Giedke H, Geilenkirchen R, Hauser M (1992) The timing of partial sleep deprivation in depression. J Affect Disord 25(2):117–128
13. Adrien J (2002) Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 6(5):341–351
14. Asikainen M, Toppila J, Alanko L, Ward DJ, Stenberg D, Porkka-Heiskanen T (1997) Sleep deprivation increases brain serotonin turnover in the rat. Neuroreport 8(7):1577–1582
15. Lima MMS, Andersen ML, Reksidler AB, Ferraz AC, Vital AM, Tufik S (2012) Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion. CNS Neurol Disord Drug Targets 11:359–368
16. Lima MM, Andersen ML, Reksidler AB, Silva A, Zager A, Zanata SM, Vital MA, Tufik S (2008) Blockage of dopaminergic D(2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation. Behav Brain Res 188(2):406–411. doi:10.1016/j.bbr.2007.11.025
17. Proenca MB, Dombrowski PA, Da Cunha C, Fischer L, Ferraz AC, Lima MM (2014) Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation. Neuropharmacology 76 Pt A:118–126. doi:10.1016/j.neuropharm.2013.08.024
18. Guzman-Marin R, Alam MN, Szymusiak R, Drucker-Colin R, Gong H, McGinty D (2000) Discharge modulation of rat dorsal raphe neurons during sleep and waking: effects of preoptic/basal forebrain warming. Brain Res 875(1–2):23–34
19. Tissier MH, Lainey E, Fattaccini CM, Hamon M, Adrien J (1993) Effects of ipsapirone, a 5-HT1A agonist, on sleep/wakefulness cycles: probable post-synaptic action. J Sleep Res 2(2):103–109
20. Vogel GW, Buffenstein A, Minter K, Hennessey A (1990) Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev 14(1):49–63
21. van Riezen H, Leonard BE (1990) Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 47(1):21–34
22. Cairncross KD, Cox B, Forster C, Wren AF (1977) The olfactory bulbectomized rat: a simple model for detecting drugs with antidepressant potential [proceedings]. Br J Pharmacol 61(3):497P
23. Machado RB, Hipolide DC, Benedito-Silva AA, Tufik S (2004) Sleep deprivation induced by the modified multiple platform technique: quantification of sleep loss and recovery. Brain Res 1004(1–2):45–51
24. Broadhurst PL (1960) Experiments in psychogenetics. In: Einsenk HJ (ed) Experiments in personality. Routledge and Kegan Paul, London, pp 52–71
25. Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47(4):379–391
26. Reneric JP, Bouvard M, Stinus L (2002) In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 136(2):521–532
27. Elfving B, Plougmann PH, Wegener G (2010) Detection of brain-derived neurotrophic factor (BDNF) in rat blood and brain preparations using ELISA: pitfalls and solutions. J Neurosci Methods 187(1):73–77. doi:10.1016/j.jneumeth.2009.12.017
28. Bertaina-Anglade V, La Rochelle CD, Scheller DK (2006) Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 548(1–3):106–114. doi:10.1016/j.ejphar.2006.07.022
29. Artaiz I, Zazpe A, Innerarity A, Del Olmo E, Diaz A, Ruiz-Ortega JA, Castro E, Pena R, Labeaga L, Pazos A, Orjales A (2005) Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties. Psychopharmacology (Berlin) 182(3):400–413. doi:10.1007/s00213-005-0087-3
30. Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, Olivier B (2009) Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol 616(1–3):134–140. doi:10.1016/j.ejphar.2009.06.029
31. Breuer ME, Groenink L, Oosting RS, Westenberg HG, Olivier B (2007) Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats. Biol Psychiatry 61(8):990–995. doi:10.1016/j.biopsych.2006.08.032
32. Sowa-Kucma M, Legutko B, Szewczyk B, Novak K, Znojek P, Poleszak E, Papp M, Pilc A, Nowak G (2008) Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm 115(12):1621–1628. doi:10.1007/s00702-008-0115-7
33. Hendriksen H, Meulendijks D, Douma TN, Bink DI, Breuer ME, Westphal KG, Olivier B, Oosting RS (2012) Environmental enrichment has antidepressant-like action without improving learning and memory deficits in olfactory bulbectomized rats. Neuropharmacology 62(1):270–277. doi:10.1016/j.neuropharm.2011.07.018
34. Pudell C, Vicente BA, Delattre AM, Carabelli B, Mori MA, Suchecki D, Machado RB, Zanata SM, Visentainer JV, de Oliveira Santos OJ, Lima MM, Ferraz AC (2013) Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats. Eur J Neurosci. doi:10.1111/ejn.12406
35. Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, Gall CM (1994) Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 342(3):321–334. doi:10.1002/cne.903420302
36. Pierce RC, Bari AA (2001) The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci 12(2):95–110
37. Sokoloff P, Guillin O, Diaz J, Carroll P, Griffon N (2002) Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders. Neurotox Res 4(7–8):671–678. doi:10.1080/1029842021000045499
38. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347(6289):146–151. doi:10.1038/347146a0
39. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11(2):58–65. doi:10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H
40. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK (2004) Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 56(1):54–60. doi:10.1016/j.biopsych.2004.03.013
41. Song C, Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29(4–5):627–647. doi:10.1016/j.neubiorev.2005.03.010
42. Uchida N, Mainen ZF (2003) Speed and accuracy of olfactory discrimination in the rat. Nat Neurosci 6(11):1224–1229. doi:10.1038/nn1142
43. Soh Z, Saito M, Kurita Y, Takiguchi N, Ohtake H, Tsuji T (2014) A comparison between the human sense of smell and neural activity in the olfactory bulb of rats. Chem Senses 39(2):91–105. doi:10.1093/chemse/bjt057
44. Ebrahim IO, Peacock KW (2005) REM sleep behavior disorder–psychiatric presentations: a case series from the United Kingdom. J Clin Sleep Med 1(1):43–47
45. Wirz-Justice A, Van den Hoofdakker RH (1999) Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 46(4):445–453
46. Southmayd SE, David MM, Cairns J, Delva NJ, Letemendia FJ, Waldron JJ (1990) Sleep deprivation in depression: pattern of relapse and characteristics of preceding sleep. Biol Psychiatry 28(11):979–988
47. Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, Picciotto MR (2013) Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc Natl Acad Sci U S A 110(9):3573–3578. doi:10.1073/pnas.1219731110
48. Gillin JC, Sutton L, Ruiz C, Kelsoe J, Dupont RM, Darko D, Risch SC, Golshan S, Janowsky D (1991) The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry 48(3):264–270
49. Basheer R, Magner M, McCarley RW, Shiromani PJ (1998) REM sleep deprivation increases the levels of tyrosine hydroxylase and norepinephrine transporter mRNA in the locus coeruleus. Brain Res Mol Brain Res 57(2):235–240
50. Shores MM, Szot P, Veith RC (1994) Desipramine-induced increase in norepinephrine transporter mRNA is not mediated via alpha 2 receptors. Brain Res Mol Brain Res 27(2):337–341
51. Fujihara H, Sei H, Morita Y, Ueta Y, Morita K (2003) Short-term sleep disturbance enhances brain-derived neurotrophic factor gene expression in rat hippocampus by acting as internal stressor. J Mol Neurosci 21(3):223–232
52. Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA (2013) Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 16(2):301–311. doi:10.1017/S1461145712000545
53. Schrag A (2004) Psychiatric aspects of Parkinson’s disease—an update. J Neurol 251(7):795–804
54. Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH, Yadid G (2005) Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 48(1):34–42
55. Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes of the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol 62(1):63–88
56. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34(1):13–25